REG - Craneware plc - Total Voting Rights

CranewareAnnouncement

02/10/2024 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241002:nRSB6852Ga&default-theme=true

RNS Number : 6852G  Craneware plc  02 October 2024

 

Craneware plc

("Craneware" or the "Company")

 

Total Voting Rights

 

2 October 2024 - Following recent share option exercise transactions by
employees, on 30 September 2024 the Company transferred a total of 439
Ordinary Shares previously held in treasury to satisfy those share option
exercise transactions.

 

As a result, the Company's issued share capital now consists of 35,542,169
Ordinary Shares, of which 199,453 remain held in treasury. Accordingly, the
total number of Ordinary Shares in the Company with voting rights is
35,342,716. This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 

 

For further information, please contact:

 

 Craneware plc                                    +44 (0)131 550 3100
 Keith Neilson, CEO
 Craig Preston, CFO

 Alma Strategic Communications (Financial PR)     +44 (0)20 3405 0205
 Caroline Forde, Kinvara Verdon                   craneware@almastrategic.com

 Peel Hunt (NOMAD and Joint Broker)               +44 (0)20 7418 8900
 Neil Patel, Benjamin Cryer, Kate Bannatyne

 Investec Bank PLC (Joint Broker)                 +44 (0)20 7597 5970
 Patrick Robb, Henry Reast, Shalin Bhamra
 ( )                                              ( )
 Berenberg (Joint Broker)                         +44 (0)20 3207 7800
 Mark Whitmore, Richard Andrews, Dan Gee-Summons

 

About Craneware

 

The Craneware Group (AIM:CRW.L), is the market leader in value cycle
solutions. For 25 years, we have collaborated with U.S. healthcare providers
to optimize revenue integrity, pricing intelligence, decision support, labor
productivity, business of pharmacy, and 340B program management. 

 

Customers choose Trisus®, a HITRUST- and SOC2 Type II-certified, SaaS
platform, to achieve operational and financial excellence in pursuit of their
healthcare mission - delivering quality care to their communities. The
Craneware Group - Transforming the Business of Healthcare.

 

Learn more at www.thecranewaregroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRQKBBBDBDDCKK